Novo Nordisk Introduces Tiered Pricing for Wegovy in U.S.

Novo Nordisk has announced a tiered pricing structure for its weight-loss drug Wegovy in the U.S. market. Effective January 5, self-paying patients can access lower doses for $149 per month and higher doses for $299 per month. This marks the company's first explicit pricing commitment for Wegovy in the United States.

洞察:
Novo Nordisk A/S , a leading pharmaceutical company based in Denmark DKDK, has unveiled a tiered pricing strategy for its weight-loss medication, Wegovy, in the United States USUS. Effective January 5, the pricing structure offers self-paying patients access to lower doses of 1.5mg and 4mg at $149 per month, while higher doses of 9mg and 25mg are priced at $299 per month. This announcement marks Novo Nordisk's first explicit pricing commitment for Wegovy in the U.S. market, the largest pharmaceutical market globally.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little